Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 1612 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2610    
    Printed88    
    Emailed2    
    PDF Downloaded344    
    Comments [Add]    

Recommend this journal

 
INVITED ARTICLE
Year : 2009  |  Volume : 51  |  Issue : 5  |  Page : 56-60

Frontiers in the pathogenesis of Alzheimer's disease


1 Department of Neurosciences, Medical University of South Carolina, 173 Ashley Avenue, BSB 403 Charleston, SC 29425
2 Department of Biochemistry and Nutrition, Central Food Technological Research Institute, Mysore - 570020, India

Correspondence Address:
Kumar Sambamurti
Department of Neurosciences, Medical University of South Carolina, 173 Ashley Avenue, BSB 403 Charleston, SC 29425.

Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21416019

Rights and PermissionsRights and Permissions

Alzheimer's disease (AD) is characterized by progressive dementia and brain deposits of the amyloid β protein (Aβ ) as senile plaques and the microtubule-associated protein, Tau, as neurofibrillary tangles (NFT). The current treatment of AD is limited to drugs that attempt to correct deficits in the cholinergic pathway or glutamate toxicity. These drugs show some improvement over a short period of time but the disease ultimately requires treatment to prevent and stop the neurodegeneration that affects multiple pathways. The currently favored hypothesis is that Aβ aggregates to toxic forms that induce neurodegeneration. Drugs that reduce Aβ successfully treat transgenic mouse models of AD, but the most promising anti-Aβ vaccination approach did not successfully treat AD in a clinical trial. These studies suggest that AD pathogenesis is a complex phenomenon and requires a more broad-based approach to identify mechanisms of neurodegeneration. Multiple hypotheses have been proposed and the field is ready for a new generation of ideas to develop early diagnostic approaches and develop successful treatment plans.



[FULL TEXT] [PDF]*

        

Print this article         Email this article